New York, NY - (ACCESSWIRE) - 11/06/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Mindspeed Technologies Inc. (NASDAQ:MSPD), InterMune Inc. (NASDAQ:ITMN), Cytori Therapeutics, Inc. (NASDAQ:CYTX), and Vringo, Inc. (NASDAQ:VRNG)
Mindspeed Technologies Inc. (NASDAQ:MSPD) a company that designs, develops, and sells semiconductor solutions for communications applications in fixed and mobile broadband access, enterprise, metropolitan, and wide-area networks is currently up (+68.86%) on 17,847,812 shares traded after MINDSPEED TECHNOLOGIES, INC Filed SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits. Mindspeed Technologies Inc. (NASDAQ:MSPD) is currently up (+120.61%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Mindspeed Technologies Inc. (NASDAQ:MSPD)
Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MSPD&SubId=AW
InterMune Inc. (NASDAQ:ITMN) a biotechnology company that engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases is currently down (-5.68%) on 2,541,243 shares traded after INTERMUNE INC Filed SEC form 8-K, Other Events, Financial Statements and Exhibits. InterMune Inc. (NASDAQ:ITMN) is currently down (-20.31%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about InterMune Inc. (NASDAQ:ITMN)
Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ITMN&SubId=AW
Cytori Therapeutics, Inc. (NASDAQ:CYTX) a cell therapy company that engages in developing cell therapies based on autologous adipose-derived regenerative cells to treat cardiovascular diseases and other medical conditions is currently down (-17.68%) on 2,823,951 shares traded after CYTORI THERAPEUTICS, INC. Filed SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits. Cytori Therapeutics, Inc. (NASDAQ:CYTX) is currently down (-32.94%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=CYTX&SubId=AW
Vringo, Inc. (NASDAQ:VRNG) a company that together with its subsidiaries, engages in the innovation, acquisition, licensing, and protection of intellectual property worldwide is currently up (+8.81%) on 2,288,445 shares traded after Vringo announced that the USPTO confirmed validity of the 664 patent asserted in litigation with AOL, Google et al.. Vringo, Inc. (NASDAQ:VRNG) is currently up (+18.01%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Vringo, Inc. (NASDAQ:VRNG)
Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=VRNG&SubId=AW
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.equityprofilereport.com/
Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Contact Info:
Equity Profile Report
editor@Equityprofilereport.com